Outcomes Study with Hospital Clínico Metropolitano La Florida is the First Step in Entering Latin American Market
Richmond, VA, August 11, 2014 –ALR Technologies Inc. (OTCQB: ALRT) announced that it had signed a Memorandum of Understanding (MOU) with the leadership of Hospital Clínico Metropolitano La Florida, one of the largest and most prestigious public hospitals in Santiago, Chile, to conduct a clinical outcomes study utilizing ALRT’s Health-e-Connect Diabetes Management System. The trial will also utilize ALRT’s latest product offering, the Insulin Dose Adjustment Consult (IDAC) feature that allows primary care physicians to access – electronically – an insulin dose recommended by an endocrinologist.
Hospital Clínico Metropolitano La Florida will enroll 100 of its insulin-requiring patients in the intervention arm of the study and 100 insulin-requiring patients in the control arm. The intervention group will utilize the Health-e-Connect System with IDAC for six months of treatment. Key data points for the study will include: average A1c reduction, adherence to medication and care plan, and physician and patient satisfaction.
The trial will be designed so that its results can be published in a premier academic medical journal with authors affiliated with both ALRT and Hospital La Florida.
Hospital Clínico Metropolitano La Florida’s Director, Dr. Midori Sawada said: “Diabetes prevalence in Chile and in Latin America is exploding. We need to find cost effective treatments to help our patients manage their disease more effectively and to raise the quality of care in our public system. We eagerly embraced a clinical trial with ALRT in order to determine the effectiveness of remote monitoring and other creative technologies that hold the potential to improve outcomes for our patients with chronic diseases.”
ALRT’s CEO Sidney Chan said: “Our Health-e-Connect System offers a real solution to the diabetes crisis in Latin America. This trial is a key strategic effort by ALRT to facilitate our penetration into emerging markets where the burgeoning diabetes pandemic is overwhelming public healthcare systems.”
Hospital Clínico Metropolitano La Florida is one of Chile’s newest and largest public hospitals in the greater Santiago area. The Hospital is managed by Chile’s Ministry of Health and is a tertiary care level Hospital offering expertise in many specialties and subspecialties, including endocrinology. The Hospital has 391 beds and is designed to meet the medical needs in the South East Network that has a population of 394,821 inhabitants, equivalent to 6.03% of the total population in the region. More information can be found here: http://www.youtube.com/watch?v=WeDqqYRHTrM
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
For more information, email us at
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange.